The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig.2 The proportion of subjects with absence of DAT deficit in clinical trials increases with earlier stages of PD. A number of PD clinical studies have identified subjects defined as SWEDD by employing DAT imaging at baseline and follow up. The proportion of subjects defined as SWEDD decreases with the time since diagnosis for those in specific PD clinical studies targeting early stages of the disease. The proportion of SWEDD subjects is lower in studies enrolling subjects with longer duration of disease. As sponsors enroll PD subjects earlier in the disease (i.e., sooner after diagnosis), the value (benefit) of DAT imaging for enrichment increases. References for PD clinical studies: [38, 39, 41, 59– 61]. ELLDOPA: Levodopa; PRECEPT: Mixed Lineage Kinase Inhibitor CEP 1347; REAL-PD: Ropinirole; CALM-PD: Pramipexole; GPI1485: Immunophilin; PPMI: Parkinson’s Progression Markers Initiative.](https://figures.cochat.ai/paper-figures/c67f8a2c856f42f3908b4d598270846f/the-qualification-of-an-enrichment-biomarker-for-clinical-trials-targeting-early-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005 · cited 1×
“Novel therapeutic development efforts are underway targeting -synuclein [11] and the two most common genetic causes of PD, glucocerebrosidase (GBA) deficiency [12], and mutated forms of leucine rich repeat kinase 2 (LRRK2) [4, 13].”
BackgroundThe Emerging Evidence of the Parkinson Pandemic
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181474 · Cited by 1,977 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundThe Parkinson Progression Marker Initiative (PPMI)
Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.005 · Cited by 1,892
Self-citationDisease duration and the integrity of the nigrostriatal system in Parkinson’s disease
Kordower, J. H., Olanow, C. W., Dodiya, H. B., Chu, Y., Beach, T. G., Adler, C. H., Halliday, G. M., & Bartus, R. T. (2013) · Brain · doi:10.1093/brain/awt192 · Cited by 1,286
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A., Simcox, E., & Turnbull, D. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 947 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundAccuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis
Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016) · Neurology · doi:10.1212/wnl.0000000000002350 · Cited by 870 · cited 1×
“It can, however, be challenging to diagnose PD, especially in early stage disease when other neurological disorders can present with similar signs and symptoms [16, 17].”
BackgroundSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Benamer, H. T. S., Patterson, J., Grosset, D. G., Booij, J., de Bruin, K., van Royen, E., Speelman, J. D., Horstink, M. H. I. M., Sips, H. J. W. A., Dierckx, R. A., et al. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<503::aid-mds1013>3.0.co;2-v · Cited by 707 · cited 1×
“Reductions of DAT radiotracer binding (DAT deficit) correlate with the disease duration from early stages of the disease [34], matching pathological findings from DAT immunohistochemistry [35].”
BackgroundSelf-citation
Research works printed but not linked: 2
- Marek K, 2003, Adv Neurol, 91, 183
- Abi-Dargham A, 1996, J Nucl Med, 37, 1129
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Prange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00942-1 · Cited by 167
“These developments will prove instrumental for the recognition of imaging biomarkers specific to PD depression, which may in turn serve as enrichment biomarkers in clinical trials [313].”
BackgroundThe Parkinson Study Group SURE-PD3 Investigators, Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., Schwarzschild, M. A., Ascherio, A., Casaceli, C., et al. (2021) · JAMA · doi:10.1001/jama.2021.10207 · Cited by 165
Self-citationBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 87
“It can limit inclusion of people who are symptomatic without evidence of dopamine degeneration (SWEDD), a group that comprises approximately 15% of cases when using clinical criteria alone 81,82 .”
Stephenson, D., Alexander, R., Aggarwal, V., Badawy, R., Bain, L., Bhatnagar, R., Bloem, B. R., Boroojerdi, B., Burton, J., Cedarbaum, J. M., et al. (2020) · Digital Biomarkers · doi:10.1159/000512500 · Cited by 63
Self-citation
Metadata
- Authors
- Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., Gallagher, J., Roach, A., Basseches, P., Grosset, D., Marek, K., & on behalf of the Critical Path for Parkinson’s Consortium
- Affiliations
- Critical Path Institute (US)
- University College London, UK
- Biogen (United States) (US)
- European Medicines Agency (NL)
- Parkinson's UK (GB)
- Institute for Neurodegenerative Disorders (US)
- Denali Therapeutics (United States) (US)
- Pfizer (United States) (US)
- Archer Daniels Midland (United States) (US)
- National Center for Toxicological Research (US)
- UCB, Brussels, Belgium
- CPP Scientific Advisor, PA, USA
- Rush University (US)
- GE Healthcare, London, UK
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Glasgow (GB)
- Corresponding author
- Stephenson, Diane
- ORCID
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-07-08
- Volume
- 9
- Issue
- 3
- Pages
- 553-563
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC6700608
- OpenAlex
- W2958884967
- Cited by
- 46
- References
- 57
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 11 · 2019: 1
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Parkinson's Disease Foundation
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Davis Phinney Foundation
- Strong
- Parkinson's UK
- University of Oxford
- Newcastle University
- University of Glasgow
- Radboud Universiteit
- H. Lundbeck A/S
- U.S. Food and Drug Administration (U18FD005320)
- Merck Sharp and Dohme
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, dopamine transporter SPECT, patient selection, European Medicines Agency, Parkinson's Progression Markers Initiative, dopaminergic deficit, trial enrichment, statistical power
- MeSH terms
- Clinical Studies as Topic, Clinical Trials as Topic, Corpus Striatum, Humans, Parkinson Disease, Societies, Medical, Biomarkers, Tomography, Emission-Computed, Single-Photon, Dopamine Plasma Membrane Transport Proteins, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. https://app.cochat.ai/papers/10.3233/jpd-191648
- The paper
- Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., . . . on behalf of the Critical Path for Parkinson’s Consortium. (2019). The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-191648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.